AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A ~~P~~pharmaceutical composition, comprising

(a)~~characterised in that it contains~~ an anticholinergic of the formula **1**



1

wherein

X^- represents a chlorine, bromine, iodine, methanesulphonate or trifluoromethanesulphonate anion;

R^1 represents hydroxy or methyl;

Ar represents phenyl or thienyl or a pharmacologically acceptable acid addition salt, solvate, or hydrate thereof;

~~in combination with~~

(b) a ~~the~~ compound of the formula **2**



2

or a pharmacologically acceptable acid addition salt, solvate, or hydrate thereof ~~optionally in the form of a pharmacologically acceptable acid addition salt thereof, optionally in the form of a solvate or hydrate~~; and

(c) ~~and~~ optionally, ~~together with~~ a pharmaceutically acceptable excipient.

Claim 2 (currently amended): The ~~P~~pharmaceutical composition according to claim 1, ~~characterised in that~~ wherein the anticholinergic of the formula **1** is a compound of the formula **1a**



1a

wherein

X $^-$ represents a chlorine, bromine, iodine, methanesulphonate or trifluoromethanesulphonate anion~~;~~.

or a pharmacologically acceptable acid addition salt, solvate, or hydrate thereof

~~optionally in the form of a pharmacologically acceptable acid addition salt thereof, optionally in the form of a solvate or hydrate and optionally together with a pharmaceutically acceptable excipient.~~

Claim 3 (currently amended): The ~~P~~pharmaceutical composition according to claim 2, wherein ~~characterised in that~~ X represents bromine.

Claim 4 (currently amended): The ~~P~~pharmaceutical composition according to claim 1, wherein ~~characterised in that~~ the anticholinergic of the formula **1** is a compound of the formula **1b**



1b

wherein

X^- represents a chlorine, bromine, iodine, methanesulphonate or trifluoromethanesulphonate anion.~~;~~

or a pharmacologically acceptable acid addition salt, solvate, or hydrate thereof

~~optionally in the form of a pharmacologically acceptable acid addition salt thereof, optionally in the form of a solvate or hydrate and optionally together with a pharmaceutically acceptable excipient~~.

Claim 5 (currently amended): The ~~P~~pharmaceutical composition according to claim 4, characterised in that X represents bromine.

Claim 6 (currently amended): The ~~P~~pharmaceutical composition according to ~~one of claims 1 to 5~~claim 1, wherein~~characterised in that~~ the anticholinergic of the formula **1** and the compound of the formula **2** are present either together in a single formulation or in two separate formulations.

Claim 7 (currently amended): The ~~P~~pharmaceutical composition according to ~~one of claims 1 to 6~~claim 1, wherein~~characterised in that~~ the weight ratios of the anticholinergic of the formula **1** to the compound of the formula **2** are in the range from 1:4000 to 8:1~~, preferably from 1:1000 to 1:1.2~~.

Claim 8 (currently amended): The ~~P~~pharmaceutical composition according to ~~one of claims 2 to 6~~claim 2, wherein~~characterised in that~~ the weight ratios of the compound of the formula **1a** to the compound of the formula **2** are in the range from ~~1:4000 to 1:2.5, preferably from 1:1000 to 1:12.5~~1:4000 to 1:2.5.

Claim 9 (currently amended): The ~~P~~pharmaceutical composition according to ~~one of claims 4 to 6~~claim 4, wherein ~~characterised in that~~ the weight ratios of the compound of the formula **1b** to the compound of the formula **2** are in the range from ~~1:4000 to 8:1, preferably from 1:1000 to 1:1.2~~1:4000 to 8:1.

Claim 10 (currently amended): The ~~P~~pharmaceutical composition according to ~~one of claims 1 to 9~~claim 1, wherein ~~characterised in that~~ the total dosage per single dose of the combination of the anticholinergic of the formula **1** and the compound of the formula **2** is ~~in the range of 25 to 10000µg, preferably~~ from ~~100 to 5800µg~~25 to 10000µg.

Claim 11 (currently amended): The ~~P~~pharmaceutical composition according to ~~one of claims 1 to 10~~claim 1, wherein the composition ~~characterised in that it~~ is in the form of a formulation suitable for inhalation.

Claim 12 (currently amended): The ~~P~~pharmaceutical composition according to claim 11, wherein the composition is a ~~characterised in that it is a~~ formulation selected from among inhalable powders, propellant-containing metering aerosols and propellant-free inhalable solutions or suspensions.

Claim 13 (currently amended): The ~~P~~pharmaceutical composition according to claim 12, wherein the composition ~~characterised in that it~~ is an inhalable powder which contains the anticholinergic of the formula **1** and the compound of the formula **2** in admixture with ~~suitable~~ physiologically acceptable excipients, including ~~selected from among the~~ monosaccharides, disaccharides, oligo- and polysaccharides, cyclodextrines, polyalcohols, salts, or mixtures ~~of these excipients with one another~~ thereof.

Claim 14 (currently amended): The Inhalable powder according to claim 13, wherein ~~characterised in that~~ the excipient has a maximum average particle size of up to 250µm~~, preferably between 10 and 150µm~~.

Claim 15 (currently amended): The ~~P~~pharmaceutical composition according to claim 12, wherein the composition is an ~~characterised in that it is an~~ inhalable powder which contains only the anticholinergic of the formula **1** and the compound of the formula **2** as its ingredients.

Claim 16 (currently amended): The ~~P~~pharmaceutical composition according to claim 12, wherein the composition ~~characterised in that it~~ is a propellant-containing inhalable aerosol which contains the anticholinergic of the formula **1** and the compound of the formula **2** in dissolved or dispersed form.

Claim 17 (currently amended): The ~~P~~pharmaceutical composition in the form of a propellant-containing inhalable aerosol according to claim 16, ~~characterised in that it contains, as propellant gas~~wherein the propellant is a, hydrocarbons ~~such as n-propane, n-butane or isobutane~~

~~or~~or a halohydrocarbons ~~such as chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane~~.

Claim 18 (currently amended): The p~~P~~harmaceutical composition in the form of a propellant-containing inhalable aerosol according to claim 17, ~~characterised in that~~ wherein the propellant gas is TG11, TG12, TG134a (1,1,1,2-tetrafluoroethane), TG227 (1,1,1,2,3,3,3-heptafluoropropane) or a mixture thereof.

Claim 19 (currently amended): The P~~p~~harmaceutical composition according to claim 12, ~~characterised in that it~~wherein the composition is a propellant-free inhalable solution or suspension which contains water, ethanol or a mixture of water and ethanol as solvent.

Claim 20 (currently amended): The P~~p~~harmaceutical composition in the form of an inhalable solution or suspension according to claim 19, ~~characterised in that~~wherein the pH is ~~2 to 7, preferably~~ 2 to 5.

Claim 21 (currently amended): A capsule comprising ~~Capsules, characterised in that they contain~~ an inhalable powder according to claim 13 ~~or 14~~.

Claims 22-24: canceled.

Claim 25 (currently amended): A method of prophylaxis of, treating of, or reducing the exacerbations associated with pulmonary diseases comprising~~by~~ administering to a patient in need thereof an effective amount of a pharmaceutical composition according to ~~one or more of the claims 1 to 20~~ claim 1 either in a single combined form, separately, or separately and sequentially where the sequential administration is close in time, or remote in time.

Claim 26 (currently amended): The method according to claim 25 wherein the pulmonary disease is asthma, COPD, or another obstructive airways disease exacerbated by bronchial hyperreactivity and bronchospasm.

Claim 27 (currently amended): The method according to claim 25 ~~or 26~~ wherein said administration by inhalation comprises simultaneous or sequential delivery of said combination of therapeutic agents, comprising the anticholinergic of the formula **1** and the compound of the formula **2**, in the form of an aerosol or dry powder dispersion.

Claim 28 (currently amended): The method according to ~~one or more of the claims~~claim 25 ~~to 27~~, wherein the anticholinergic of the formula **1** is the compound of the formula **1a**.

Claim 29 (currently amended): The method according to ~~one or more of the claims~~claim 25 ~~to 27~~, wherein the anticholinergic of the formula **1** is the compound of the formula **1b**.

Claim 30 (currently amended): A package comprising a pharmaceutical composition according to ~~one or more of the claims~~claim 1 ~~to 22~~ for insertion into a device of simultaneous or sequential delivery of said pharmaceutical composition in the form of an aerosol or dry powder dispersion, to a mammal in need ~~of treatment~~ thereof.

Claim 31 (currently amended): An Inhaler comprising a pharmaceutical composition according to ~~one or more of the claims~~claim 1 ~~to 22~~ for simultaneous or sequential delivery of said pharmaceutical composition in the form of an aerosol or dry powder dispersion, to a mammal in need thereof ~~of treatment~~.

Claim 32 (currently amended): A Pharmaceutical composition, ~~characterised in that it contains~~ comprising an anticholinergic in combination with the compound of the formula **2** optionally in the form of a pharmacologically acceptable acid additions~~ddition~~ salt thereof,

optionally in the form of a solvate or hydrate and optionally together with a pharmaceutically acceptable excipient.

Claims 33-37: canceled.